Fgf23; fibroblast growth factor 23; ADHR; HPDR2; HYPF; PHPTC; FGF-23; phosphatonin; tumor-derived hypophosphatemia inducing factor; tumor-derived hypophosphatemia-inducing factor; ADHR antibody; FGF-23 antibody; fibroblast growth factor 23 antibody; HPDR2 antibody; HYPF antibody; phosphatonin antibody; PHPTC antibody; tumor-derived hypophosphatemia inducing factor antibody; tumor-derived hypophosphatemia-inducing factor antibody; Fgf23 antibody; Fgf23 (mouse)

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-Fgf23 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 16000.
Western Blot: Approx 27+38kDa bands observed in Mouse Brain lysates (calculated MW of 27.7kDa according to NP_073148.1). The observed molecular weight corresponds to earlier findings in literature with different antibodies (Garringer et al, Am J Physiol Endocrinol Metab.2008 Oct;295(4): E929-37. PMID: 18682534). Recommended concentration: 0.5-2ug/ml.

(0.5ug/ml) staining of Mouse Brain lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

27,758 Da

fibroblast growth factor 23

fibroblast growth factor 23

Fibroblast growth factor 23

FGF-23??[Similar Products]

FGF23_MOUSE

This gene encodes a member of the fibroblast growth factor family. The encoded protein regulates phosphate homeostasis and vitamin D metabolism. Mutation of the related gene in humans causes autosomal dominant hypophosphatemic rickets (ADHR). The secreted protein is further cleaved into N- and C-terminal chains, which results in loss of function. [provided by RefSeq, Mar 2013]

FGF23: Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. Defects in FGF23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR). ADHR is characterized by low serum phosphorus concentrations, rickets, osteomalacia, leg deformities, short stature, bone pain and dental abscesses. Defects in FGF23 are a cause of hyperphosphatemic familial tumoral calcinosis (HFTC). HFTC is a severe autosomal recessive metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Belongs to the heparin-binding growth factors family.

Protein type: Secreted, signal peptide; Cytokine; Secreted

Cellular Component: extracellular region; extracellular space

Molecular Function: fibroblast growth factor receptor binding; growth factor activity; protein binding; type 1 fibroblast growth factor receptor binding

Biological Process: cell differentiation; cellular phosphate ion homeostasis; fibroblast growth factor receptor signaling pathway; MAPKKK cascade; negative regulation of bone mineralization; negative regulation of hormone secretion; negative regulation of osteoblast differentiation; phosphate ion homeostasis; positive regulation of transcription, DNA-dependent; regulation of bone mineralization; vitamin D catabolic process

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.